findmyKOL

Daniel Petro

Basic profile

UPMC Hillman Cancer Center

ORCIDNone on fileNPI
RegionPittsburgh, PA · NortheastSpecialtyHematology / OncologyFocusOncology
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Daniel Petro is an Oncology physician affiliated with UPMC Hillman Cancer Center. OpenAlex indexes 44 publications with 629 citations (h-index 13).

Overview

Scholarship

indexed output and impact (OpenAlex)
44publications

Distinct works indexed by OpenAlex.

629citations

Total citations across indexed works.

13h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

2 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    39%
    Opioid Agonist22.7%
    Oxycodone Hcl100%
    Part D23 patients
    Gabapentinoids8.5%
    Gabapentin100%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    38.3%
    Serotonin-3 Receptor Antagonist13.5%
    Ondansetron Hcl100%
    Part D17 patients
    Proton pump inhibitor13.5%
    Pantoprazole Sodium100%
    Part D13 patients

    + 1 more class in this area

  • Hormonal (systemic)

    12.1%
    l-Thyroxine12.1%
    Levothyroxine Sodium100%
    Part D<11 patients
Where care is delivered (Part B)66.7% facility · 33.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”